CH
Live price temporarily unavailable.
Price history
Chemed (CHE) is a Health Care company in the Russell 1000. Latest news and coverage below.
Chemed revenue & net income history (FY2016–FY2025)
RevenueNet income
| FY2016Dec 2016 | FY2017Dec 2017 | FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $1.58B | $1.67B | $1.78B | $1.94B | $2.08B | $2.14B | $2.13B | $2.26B | $2.43B | $2.53B |
| Growth (year over year) | +2.2% | +5.7% | +7.0% | +8.7% | +7.3% | +2.9% | −0.2% | +6.1% | +7.4% | +4.1% |
| Gross profit | $461.4M | $516.2M | $555.0M | $617.4M | $701.4M | $769.8M | $765.1M | $798.8M | $854.3M | $823.2M |
| Gross margin | 29.3% | 31.0% | 31.1% | 31.8% | 33.7% | 36.0% | 35.8% | 35.3% | 35.1% | 32.5% |
| Operating income | $178.7M | $113.0M | $243.6M | $257.4M | $389.7M | $343.0M | $343.5M | $340.6M | $366.5M | $338.2M |
| Operating margin | 11.3% | 6.8% | 13.7% | 13.3% | 18.7% | 16.0% | 16.1% | 15.0% | 15.1% | 13.4% |
| Net income | $108.7M | $98.2M | $205.5M | $219.9M | $319.5M | $268.6M | $249.6M | $272.5M | $302.0M | $265.2M |
| Net margin | 6.9% | 5.9% | 11.5% | 11.3% | 15.4% | 12.6% | 11.7% | 12.0% | 12.4% | 10.5% |
| EPS (diluted) | $6.48 | $5.86 | $12.23 | $13.31 | $19.48 | $16.85 | $16.53 | $17.93 | $19.89 | $18.34 |
| Balance sheet | ||||||||||
| Cash and equivalents | $15.3M | $11.1M | $4.83M | $6.16M | $162.7M | $32.9M | $74.1M | $264.0M | $178.3M | $74.5M |
| Total assets | $880.1M | $920.0M | $975.5M | $1.27B | $1.43B | $1.34B | $1.44B | $1.67B | $1.67B | $1.54B |
| Total liabilities | $356.0M | $379.7M | $384.2M | $541.7M | $533.7M | $719.5M | $643.3M | $560.2M | $549.6M | $558.8M |
| Long-term debt | $100.0M | $91.2M | $89.2M | $90.0M | — | $185.0M | $92.5M | — | — | — |
| Shareholders' equity | $524.1M | $540.4M | $591.3M | $726.6M | $901.2M | $623.3M | $798.7M | $1.11B | $1.12B | $979.4M |
| Cash flow | ||||||||||
| Operating cash flow | $135.4M | $162.5M | $287.1M | $301.2M | $489.3M | $308.6M | $309.9M | $330.3M | $417.5M | $388.3M |
| Capital expenditure | $39.8M | $64.3M | $52.9M | $53.0M | $58.8M | $58.7M | $57.3M | $56.9M | $49.5M | $62.8M |
| Free cash flow | $95.6M | $98.2M | $234.3M | $248.2M | $430.5M | $249.9M | $252.6M | $273.4M | $368.0M | $325.5M |
| Dividends paid | $16.4M | $17.4M | $18.7M | $19.8M | $21.1M | $22.0M | $22.0M | $23.5M | $27.1M | $31.7M |
| Share buybacks | $102.3M | $94.6M | $158.9M | $92.6M | $175.6M | $576.0M | $114.5M | $67.7M | $361.4M | $431.5M |
RevenueNet income
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $606.2M | $640.0M | $646.9M | $618.8M | $624.9M | $639.3M | $657.5M | $673.3M |
| Growth (year over year) | +7.4% | +9.2% | +9.8% | +3.8% | +3.1% | −0.1% | +1.6% | +8.8% |
| Gross profit | $210.0M | $234.1M | $216.4M | $184.7M | $196.9M | $225.2M | $215.8M | $221.5M |
| Gross margin | 34.6% | 36.6% | 33.5% | 29.8% | 31.5% | 35.2% | 32.8% | 32.9% |
| Operating income | $92.2M | $113.9M | $94.8M | $68.1M | $74.8M | $100.7M | $84.6M | $89.2M |
| Operating margin | 15.2% | 17.8% | 14.6% | 11.0% | 12.0% | 15.7% | 12.9% | 13.2% |
| Net income | $75.8M | $90.3M | $71.8M | $52.5M | $64.2M | $76.8M | $66.3M | $67.7M |
| Net margin | 12.5% | 14.1% | 11.1% | 8.5% | 10.3% | 12.0% | 10.1% | 10.1% |
| EPS (diluted) | $5.00 | $6.00 | $4.86 | $3.57 | $4.46 | $5.45 | $4.84 | $5.13 |
| Balance sheet | ||||||||
| Cash and equivalents | $238.5M | $178.3M | $173.9M | $249.9M | $129.8M | $74.5M | $16.9M | $40.2M |
| Total assets | $1.77B | $1.67B | $1.73B | $1.72B | $1.62B | $1.54B | $1.54B | $1.58B |
| Total liabilities | $533.7M | $549.6M | $544.8M | $519.4M | $546.9M | $558.8M | $687.8M | $749.1M |
| Long-term debt | — | — | — | — | — | — | $91.2M | $140.0M |
| Shareholders' equity | $1.24B | $1.12B | $1.18B | $1.20B | $1.08B | $979.4M | $848.0M | $830.5M |
| Cash flow | ||||||||
| Operating cash flow | $90.5M | $164.9M | $32.7M | $138.6M | $83.4M | $133.5M | $88.2M | $84.8M |
| Capital expenditure | $18.6M | −$77.7M | $13.3M | $15.8M | $17.5M | $16.2M | $17.1M | $15.5M |
| Free cash flow | $71.9M | $242.6M | $19.5M | $122.8M | $65.9M | $117.3M | $71.1M | $69.3M |
| Dividends paid | $7.49M | $7.50M | $7.33M | $7.22M | $8.65M | $8.50M | $8.17M | $7.88M |
| Share buybacks | $57.8M | $209.3M | $33.2M | $42.9M | $180.8M | $174.6M | $190.0M | $97.5M |
From Chemed's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About Chemed
- Headquarters
- Cincinnati, Ohio From SEC filings, Oct 2026
Recent News (1)
More Health Care stocks
- ILMN Illumina
- A Agilent Technologies
- ABBV AbbVie
- ABT Abbott Laboratories
- ALGN Align Technology
- ALNY Alnylam Pharmaceuticals
- AMGN Amgen
- BAX Baxter International